| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/25/2006 | US7081471 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 07/25/2006 | US7081470 Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| 07/25/2006 | US7081469 Therapy for neovascularization; antitumor agents; vision defects; antidiabetic agents; antiarthritic agents |
| 07/25/2006 | US7081468 Angiogenesis inhibitors; antitumor agents; skin disorders; antiarthritic agents |
| 07/25/2006 | US7081467 C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals |
| 07/25/2006 | US7081466 anticarcinogenic agents with improved efficacy against multidrug resistant tumors; improved oral bioavailability and side effect reduction |
| 07/25/2006 | US7081465 Alpha-substituted naphthyloxy omega-substituted alky/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders |
| 07/25/2006 | US7081464 enzyme inhibitors of tumor necrosis factor alpha and phosphodiesterase; anticachetic, antiasthmatic, antiinflammatory agents |
| 07/25/2006 | US7081463 Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders |
| 07/25/2006 | US7081462 Imidazo-substituted compounds as p38 kinase inhibitors |
| 07/25/2006 | US7081461 Quinazoline compounds and pharmaceutical compositions containing them |
| 07/25/2006 | US7081460 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
| 07/25/2006 | US7081459 1-substituted pyridine-2-ones or 2-substituted pyridazin-3-ones; anticarcinogenic agents for breast and prostate cancer; contraceptives; endometriosis, benign prostatic hypertophy |
| 07/25/2006 | US7081458 Small molecule, non-peptide antagonists; antidiabetic agents; obesity; {5-[1-4-Methoxy-2,3-dimethyl-phenyl)-ethyl]-(1S,4S)-2,5-diaza-bicyclo[2.2.1]hept-2-yl}-(4-trifluoromethyl-phenyl)-methanone |
| 07/25/2006 | US7081457 Contraceptives; hormone replacement therapy |
| 07/25/2006 | US7081456 N-substitued-4-(3-oxo(thio)chromeno[4,3-c]pyrazol-2(3H)-yl) benzamides or N-substituted-4-(3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl) benzamides; CD80 antigen antagonists capable of inhibiting the interactions between CD80 and CD28 |
| 07/25/2006 | US7081454 Anticancer agents |
| 07/25/2006 | US7081453 Compounds for treating impaired fundic relaxation |
| 07/25/2006 | US7081452 Diagnosis, therapy, image of celluloar disorders; antitumor agents |
| 07/25/2006 | US7081451 On solid adsorbent supports; loading process can take place continuously over a period of weeks until the column is saturated |
| 07/25/2006 | US7081450 Water insoluble or soluble active compound wrapped with an amphiphilic polymer in a non-crystalline manner toform a nano-sized molecular entity in which no valent bonds are formed |
| 07/25/2006 | US7081449 Induce apoptosis; anticancer agents |
| 07/25/2006 | US7081448 N-Benzyl-octa-O-acetyl-lactobionamide or salt for example; drug for restenosis |
| 07/25/2006 | US7081345 For use in diagnostic, prognostic, prophylactic or therapeutic formulation |
| 07/25/2006 | US7081261 Crystal structure, enzyme resistance, nonhydrolyzing, nonabsorption in the small intestine, and passes into the large intestine, fermentation by colonic microflora to maintain colonic health |
| 07/25/2006 | US7081260 α-Glucosidase inhibitors from a natural source |
| 07/25/2006 | US7081258 Composition for promoting hair growth |
| 07/25/2006 | US7081256 Quinolinone derivative pharmaceutical compositon and production method therefor |
| 07/25/2006 | US7081255 Antifungal compositions with improved bioavailability |
| 07/25/2006 | US7081254 For relieving or improving skin roughness and suppressing wrinkling, shows neither any offensive smell nor stickiness, gives users a dry feel upon use, and exhibits controlled foaming upon production and stability |
| 07/25/2006 | US7081252 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
| 07/25/2006 | US7081251 Administering as a transdermal patch comprising oxybutynin to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1 with a peak oxybutynin metabolite plasma concentration of less than about 8 ng/ml |
| 07/25/2006 | US7081250 Administering as a transdermal patch comprising oxybutynin to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1 with a peak oxybutynin metabolite plasma concentration of less than about 8 ng/ml |
| 07/25/2006 | US7081249 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
| 07/25/2006 | US7081248 A nonaqueous mixture comprising a precursor of vitamins E and A, and vitamin D3 for treating animal |
| 07/25/2006 | US7081246 Stable hydroalcoholic compositions |
| 07/25/2006 | US7081240 Protein mixtures for wound healing |
| 07/25/2006 | US7081239 Administering formulation comprising peptide YY or antagonists of receptors for peptide YY for manipulating the rate of upper gastrointestinal transit of a substance in a mammal having an intrinsic cholinergic afferent neural pathway |
| 07/25/2006 | CA2395869C 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives |
| 07/25/2006 | CA2369095C Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders |
| 07/25/2006 | CA2289209C Cyclic ether vitamin d3 compounds, 1.alpha. (oh) 3-epi-vitamin d3 compounds and uses thereof |
| 07/25/2006 | CA2283663C Benzocycloheptathiophene compounds |
| 07/25/2006 | CA2263328C Use of .gamma.-hydroxybutyric acid amides in the treatment of drug addiction and in particular of alcoholism |
| 07/25/2006 | CA2259218C Tetrahydrobenzindole compound |
| 07/25/2006 | CA2253330C 6-o-substituted erythromycin compounds and method for making same |
| 07/25/2006 | CA2245630C Composition and method for effecting superficial chemical skin peels |
| 07/25/2006 | CA2242354C Pyrrolopyrimidines and processes for their preparation |
| 07/25/2006 | CA2207652C Hemolysis prevention by surfactants and emulsions |
| 07/25/2006 | CA2186245C Glucosidic derivatives of n-acyl alkylamines exerting neuroprotective, neurotrophic and anti-inflammatory action, useful in acute and chronic disorders of the central nervous system connected with excitotoxicity |
| 07/25/2006 | CA2182812C Pharmaceutical composition for systemic transdermal administration containing the active agent morphine-6-glucuronide |
| 07/25/2006 | CA2178107C Compositions for topical application to skin, hair or nails |
| 07/25/2006 | CA2168921C 1,6-naphthyridonecarboxylic acid derivatives |
| 07/25/2006 | CA2161138C Oxidation products of cephalomannine |
| 07/25/2006 | CA2159603C Quinolines as type iv phosphodiesterase inhibitors |
| 07/25/2006 | CA2159192C Immunomodulator cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases |
| 07/25/2006 | CA2133140C Isoxazole derivatives |
| 07/25/2006 | CA2129564C 2-.beta.-alkenyl penam sulfones as .beta.-lactamase inhibitors |
| 07/25/2006 | CA2072785C Pharmacologically active hydrazine derivatives and processes for the preparation thereof |
| 07/21/2006 | CA2494209A1 Radiosensitizer formulations and methods for use |
| 07/20/2006 | WO2006076734A2 Prodrugs of short-chain fatty acids and treatment methods |
| 07/20/2006 | WO2006076726A1 Synthesis of sodium narcistatin and related compounds |
| 07/20/2006 | WO2006076702A1 MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ĸB ACTIVITY AND USE THEREOF |
| 07/20/2006 | WO2006076695A2 Genetic screening for improving treatment of patients diagnosed with depression |
| 07/20/2006 | WO2006076663A2 Kits and improved compositions for treating lower urinary tract |
| 07/20/2006 | WO2006076659A2 Composition and method for covalently coupling a substance to a substrate |
| 07/20/2006 | WO2006076655A2 Use of alpha-2 adrenergic receptor agonists |
| 07/20/2006 | WO2006076646A2 Heteroaryl substituted quinolin-4-ylamine analogues |
| 07/20/2006 | WO2006076644A2 Heteroaryl sulfonamides and ccr2 |
| 07/20/2006 | WO2006076633A1 MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF |
| 07/20/2006 | WO2006076630A1 N-((2z)-2-((4-hydroxyphenyl)imino)-1,2-dihydro-3-pyridinyl)-4-methoxybenzenesulfonamide crystalline form 2 |
| 07/20/2006 | WO2006076598A2 Bicyclic heterocycles as cannabinoid receptor modulators |
| 07/20/2006 | WO2006076597A1 Bicyclic heterocycles as cannabinoid receptor modulators |
| 07/20/2006 | WO2006076595A1 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| 07/20/2006 | WO2006076593A1 1,3-diaryl substituted ureas as modulators of kinase activity |
| 07/20/2006 | WO2006076592A1 1,3 substituted diaryl ureas as modulators of kinase activity |
| 07/20/2006 | WO2006076580A2 A method of modulating t cell functioning |
| 07/20/2006 | WO2006076560A1 Polymorphs of memantine hydrochloride |
| 07/20/2006 | WO2006076529A1 Indole derivatives for treating viral infections |
| 07/20/2006 | WO2006076511A1 N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide crystalline form 1 |
| 07/20/2006 | WO2006076509A1 Heterocyclic modulators of the glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof |
| 07/20/2006 | WO2006076494A1 Catalpic acid for the treatment of type 2 diabetes and associated disorders |
| 07/20/2006 | WO2006076442A2 Triazolopyrimidine derivatives |
| 07/20/2006 | WO2006076434A2 Improved cox-2 inhibitory compositions and therapeutic regimen |
| 07/20/2006 | WO2006076433A1 A triacylglyceride to deliver health promoting fatty acids to the upper gastrointestinal tract and skin |
| 07/20/2006 | WO2006076387A2 Cyanidin-3-glucoside as an anti-neoplastic agent |
| 07/20/2006 | WO2006076376A1 Topical treatment of solid tumors and ocular neovascularization |
| 07/20/2006 | WO2006076338A2 Dosage form for treating gastrointestinal disorders |
| 07/20/2006 | WO2006076337A1 Prodrugs and conjugates of thiol- and selenol- containing compounds and methods of use thereof |
| 07/20/2006 | WO2006076318A1 Monopotassium salt of an ikb kinase inhibitor |
| 07/20/2006 | WO2006076317A2 Aminophenyl derivatives as selective androgen receptor modulators |
| 07/20/2006 | WO2006076308A1 Dry eye treatment |
| 07/20/2006 | WO2006076284A2 AMINO-IMIDAZOLONES FOR THE INHIBITION OF ß-SECRETASE |
| 07/20/2006 | WO2006076277A1 Compositions and methods for increasing the bioavailability of pulmonarily administered insulin |
| 07/20/2006 | WO2006076246A2 Phenylglycinamide derivatives useful as anticoagulants |
| 07/20/2006 | WO2006076240A2 Compositions, products and methods for controlling weight in a mammal |
| 07/20/2006 | WO2006076231A2 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level |
| 07/20/2006 | WO2006076216A2 Apoptosis-inducing antineoplastic silver (i) coordination complexes |
| 07/20/2006 | WO2006076202A1 Heterocyclic carboxamide compounds as steroid nuclear receptors ligands |
| 07/20/2006 | WO2006076169A2 Treatment or prevention of genital viral infections with immunomodulator compounds |
| 07/20/2006 | WO2006076131A2 Chemical compounds |